By Lina carolina 
A groundbreaking MRI-based imaging technique developed at the University of Cambridge has demonstrated remarkable success in predicting how ovarian cancer tumours will respond to treatment, and crucially, in rapidly assessing the efficacy of that treatment within patient-derived cell models. This innovative approach, known as hyperpolarised carbon-13 imaging, has the potential to revolutionize the management of ovarian cancer, offering oncologists unprecedented speed and accuracy in tailoring treatments to individual patients. The findings, published today in the esteemed journal Oncogene, represent a significant leap forward in the fight against one of the deadliest cancers affecting women.
Accelerating Treatment Decisions: The Power of Hyperpolarised Imaging
The core of this breakthrough lies in hyperpolarised carbon-13 imaging’s extraordinary ability to amplify the signal detected by an MRI scanner by over 10,000 times. This dramatic enhancement allows scientists to visualize metabolic processes within tumours with unparalleled clarity. In their latest study, researchers utilized this technique to examine patient-derived cell models that meticulously replicate the complex behavior of high-grade serous ovarian cancer (HGSOC), the most common and aggressive form of the disease.
The results were compelling: the hyperpolarised imaging technique was able to clearly distinguish between two distinct subtypes of ovarian cancer, revealing their differential sensitivities to Carboplatin, a cornerstone of first-line chemotherapy for ovarian cancer. This diagnostic capability means that oncologists could soon be able to predict a patient’s likely response to treatment before therapy even begins, and crucially, to ascertain how well the treatment is working within a mere 48 hours of its initiation.
This rapid feedback loop is a stark contrast to current diagnostic timelines. Typically, patients and their medical teams must wait weeks, or even months, for conventional tests to reveal whether a chosen treatment is effective. The slow pace of this feedback often means that patients with resistant tumours are exposed to ineffective and potentially toxic therapies for an extended period, delaying the introduction of more appropriate interventions. The hyperpolarised imaging technique promises to drastically shorten this window, enabling oncologists to adjust and personalize treatment strategies within days, thereby maximizing the chances of positive outcomes.
Outperforming Existing Technologies: A Comparative Analysis
In a critical part of their research, the Cambridge team directly compared the performance of their hyperpolarised imaging technique against Positron Emission Tomography (PET) scans, a modality already established in clinical practice for cancer imaging. The study’s findings indicated that PET scans, while valuable for detecting the presence and spread of tumours, failed to identify the subtle metabolic differences that characterize different ovarian cancer subtypes. Consequently, PET scans were unable to predict the specific type of tumour present or its likely response to therapy. This highlights a significant unmet need in current diagnostic capabilities, a need that hyperpolarised carbon-13 imaging appears poised to fill.
Understanding the Mechanism: From Pyruvate to Lactate
The science behind hyperpolarised carbon-13 imaging is rooted in the visualization of metabolic pathways. The technique involves injecting patients with an injectable solution containing a specially ‘labelled’ form of pyruvate, a naturally occurring molecule within the body. Once pyruvate enters the body’s cells, the MRI scanner tracks the rate at which it is metabolized into lactate. This rate of metabolism is directly linked to the aggressiveness and subtype of the tumour, providing a metabolic fingerprint that dictates its sensitivity or resistance to specific chemotherapy drugs. By quantifying this metabolic conversion, the technique offers a direct window into the living biology of the tumour, going beyond purely anatomical imaging.
A Holistic Approach to Treatment: Addressing Tumour Heterogeneity
Professor Kevin Brindle, senior author of the report and a leading figure in the Department of Biochemistry at the University of Cambridge, emphasized the technique’s potential to provide a more comprehensive understanding of the disease. "This technique tells us how aggressive an ovarian cancer tumour is," Professor Brindle stated, "and could allow doctors to assess multiple tumours in a patient to give a more holistic assessment of disease prognosis, so the most appropriate treatment can be selected."
Ovarian cancer often presents as multiple tumours spread throughout the abdominal cavity. Biopsying each of these tumours is often impractical, if not impossible, and these disseminated tumours may even comprise different subtypes with varying responses to treatment. MRI, being a non-invasive imaging modality, combined with the hyperpolarised imaging technique, offers the distinct advantage of visualizing all these tumours simultaneously, providing a unified picture of the disease burden and its metabolic landscape.
Professor Brindle further elaborated on the sequential application of the technique: "We can image a tumour pre-treatment to predict how likely it is to respond, and then we can image again immediately after treatment to confirm whether it has indeed responded. This will help doctors to select the most appropriate treatment for each patient and adjust this as necessary." He underscored the profound impact this could have on patient care: "One of the questions cancer patients ask most often is whether their treatment is working. If oncologists can speed their patients onto the best treatment, then it’s clearly of benefit."
Broader Implications and Future Directions
The implications of this research extend beyond ovarian cancer. Professor Brindle and his team at the Cancer Research UK Cambridge Institute have been at the forefront of developing hyperpolarised carbon-13 imaging for various cancers for the past two decades. This includes promising applications in breast cancer, prostate cancer, and glioblastoma, an aggressive brain tumour. Glioblastoma, much like ovarian cancer, exhibits diverse subtypes with varying metabolic profiles that can be effectively imaged to predict treatment response. Indeed, the first clinical study utilizing this technique in Cambridge, published in 2020, focused on breast cancer patients, further solidifying the technique’s potential for broad clinical utility.
The study’s publication in Oncogene marks a significant milestone, adding substantial evidence to the growing body of work supporting the widespread clinical adoption of hyperpolarised carbon-13 imaging. The next crucial step, according to the researchers, is to translate these promising findings from laboratory cell models to actual human patients. They anticipate initiating clinical trials in ovarian cancer patients within the next few years, a development eagerly awaited by the oncology community.
The Ovarian Cancer Landscape: A Pressing Need for Innovation
The urgency for such advancements in ovarian cancer treatment is underscored by sobering statistics. In the UK alone, approximately 7,500 women are diagnosed with ovarian cancer annually. Alarmingly, around 5,000 of these cases involve the most aggressive form, high-grade serous ovarian cancer (HGSOC). The overall cure rate for all forms of ovarian cancer remains disappointingly low, with only about 43% of women in England surviving for five years or more beyond their diagnosis.
A significant challenge in combating ovarian cancer is the often-subtle nature of its early symptoms, which can lead to delayed diagnosis. By the time a diagnosis is made, the disease has frequently spread, making treatment considerably more complex and less effective. This context amplifies the importance of imaging technologies that can provide rapid, accurate information about tumour behavior and treatment response, thereby optimizing the limited window for effective intervention.
The development of hyperpolarised carbon-13 imaging represents a beacon of hope in this challenging landscape. By providing an unprecedented ability to peer into the metabolic workings of ovarian tumours, this Cambridge-led innovation has the potential to usher in a new era of personalized, efficient, and ultimately more effective cancer care for countless women worldwide. The journey from laboratory bench to bedside is a complex one, but the robust findings published today suggest that this transformative technology is well on its way to becoming a vital tool in the oncologists’ arsenal.
